Structure of Lenvatinib
CAS No.: 417716-92-8
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that targets VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, showing potent antitumor activities.
Synonyms: E7080; ER-203492-00
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 417716-92-8 |
Formula : | C21H19ClN4O4 |
M.W : | 426.85 |
SMILES Code : | O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N |
Synonyms : |
E7080; ER-203492-00
|
MDL No. : | MFCD16038644 |
InChI Key : | WOSKHXYHFSIKNG-UHFFFAOYSA-N |
Pubchem ID : | 9823820 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
TPC-1 | 15 nM | Establish lenvatinib-resistant cell lines and analyze resistance mechanisms | PMC9459297 | |
FRO | 30 nM | Establish lenvatinib-resistant cell lines and analyze resistance mechanisms | PMC9459297 | |
SMMC-7721 | 10 μM | 24 h | To evaluate the effect of Lenvatinib on STOML2 expression, it was found that Lenvatinib significantly upregulated STOML2 expression | PMC7807703 |
HCCLM3 | 10 μM | 24 h | To evaluate the effect of Lenvatinib on STOML2 expression, it was found that Lenvatinib significantly upregulated STOML2 expression | PMC7807703 |
HepG2 cells | 80 μM | 14 days | To identify key genes associated with Lenvatinib resistance, it was found that DUSP4 deficiency enhanced Lenvatinib resistance and maintained cell proliferation, survival, and migration ability. | PMC9295068 |
Huh7 cells | 20 μM | 24 h | To validate the role of DUSP4 in Lenvatinib resistance, it was found that DUSP4 deficiency enhanced Lenvatinib resistance and maintained cell proliferation, survival, and migration ability. | PMC9295068 |
Hep3B cells | 10 μM | 48 h | To evaluate the effect of Lenvatinib on apoptosis in Hep3B cells, results showed that Lenvatinib induced apoptosis. | PMC8891362 |
Hep3B/CSQT-2 cells | 2.5 μM | 7 days | To evaluate the effect of Lenvatinib on colony growth in Hep3B/CSQT-2 cells, results showed that Lenvatinib inhibited colony growth. | PMC8891362 |
Caki-1 cells | 20 μM | 72 h | To study the effect of Lenvatinib on the viability of renal cancer cells, results showed that Lenvatinib significantly decreased the viability of renal cancer cells | PMC9104196 |
786-O cells | 20 μM | 72 h | To study the effect of Lenvatinib on the viability of renal cancer cells, results showed that Lenvatinib significantly decreased the viability of renal cancer cells | PMC9104196 |
A-498 cells | 20 μM | 72 h | To study the effect of Lenvatinib on the viability of renal cancer cells, results showed that Lenvatinib significantly decreased the viability of renal cancer cells | PMC9104196 |
HepG2 cells | 20 or 40 μM | 48 h | To evaluate the cytotoxicity of Lenvatinib on HepG2 cells, the results showed that 20 μM of Lenvatinib had a limited role in inducing apoptosis. | PMC9936410 |
Huh7 cells | 20 or 40 μM | 48 h | To evaluate the cytotoxicity of Lenvatinib on Huh7 cells, the results showed that both 20 and 40 μM of Lenvatinib significantly induced apoptosis. | PMC9936410 |
PLC/PRF5 cells | 20 or 40 μM | 48 h | To evaluate the cytotoxicity of Lenvatinib on PLC/PRF5 cells, the results showed that 20 μM of Lenvatinib had a limited role in inducing apoptosis. | PMC9936410 |
Hep3B cells | 20 or 40 μM | 48 h | To evaluate the cytotoxicity of Lenvatinib on Hep3B cells, the results showed that both 20 and 40 μM of Lenvatinib significantly induced apoptosis. | PMC9936410 |
HCCLM3 | 0.00001, 0.0001, 0.001, 0.01, 1, 10 and 100 μM | 72 h | To evaluate the sensitivity of HCC cells to Lenvatinib, the results showed that HCC cells with high TBC1D31 expression significantly increased resistance to Lenvatinib. | PMC11516053 |
HepG2 | 0.00001, 0.0001, 0.001, 0.01, 1, 10 and 100 μM | 72 h | To evaluate the sensitivity of HCC cells to Lenvatinib, the results showed that HCC cells with high TBC1D31 expression significantly increased resistance to Lenvatinib. | PMC11516053 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
BALB/c-nu nude mice | TPC-1/LR tumor xenograft model | oral | 6 mg/kg | once daily for 9 days | Evaluate the antitumor effect of lenvatinib and lapatinib combination on TPC-1/LR tumors | PMC9459297 |
Mice | 8505 C cell xenograft model | Oral | 25 mg/kg | Once daily for 3 weeks | To evaluate the efficacy of Lenvatinib in combination with BRAF inhibitor PLX4720 for the treatment of BRAF-mutant thyroid cancer. The results showed that Lenvatinib monotherapy significantly suppressed tumor growth, and the inhibitory effect of PLX4720 was further enhanced when combined with Lenvatinib. | PMC11127897 |
nude mice | HCCLM3 xenograft model | intraperitoneal injection | 5 mg/kg or 10 mg/kg | daily until the end of the experiment | To evaluate the inhibitory effect of Lenvatinib on HCC growth, it was found that Lenvatinib significantly suppressed tumor growth, and the combination with hydroxychloroquine was more effective | PMC7807703 |
BALB/C nude mice | Xenograft tumor model | Oral gavage | 30 mg/kg/d | Daily for 4 weeks | To evaluate the effect of DUSP4 deficiency on Lenvatinib resistance, it was found that DUSP4 deficiency impaired the anti-tumor effects of Lenvatinib and enhanced tumor growth. | PMC9295068 |
Mice | Hepa1-6 hepatoma orthotopic model | Oral | 10 mg/kg | Once daily for two weeks | To evaluate the anti-angiogenic effects of Lenvatinib on tumor angiogenesis, the results showed that Lenvatinib significantly inhibited tumor angiogenesis. | PMC10831275 |
Nude mice | PDX model | Intraperitoneal injection | 60 mg/kg | Daily for 24 days | To evaluate the effect of Lenvatinib on tumor growth in PDX model, results showed that Lenvatinib significantly inhibited tumor growth. | PMC8891362 |
BALB/c nude mice | Huh7 cell xenograft model | Intragastric administration | 10 or 30 mg/kg | Once daily for two weeks | To evaluate the anti-tumor effect of Lenvatinib in vivo on the Huh7 cell xenograft model, the results showed that both 10 and 30 mg/kg/d of Lenvatinib significantly inhibited tumor growth. | PMC9936410 |
Nude mice | HCC cell line-derived xenograft model | Oral | 4 mg/kg | Every 5 days until tumor volume reaches 1500 mm3 | To evaluate the effect of TBC1D31 knockdown on the anti-tumor efficacy of Lenvatinib, the results showed that TBC1D31 knockdown significantly increased the sensitivity of HCCLM3 cells to Lenvatinib. | PMC11516053 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT06435013 | Hepatocellular Carcinoma|Lenva... More >>tinib Less << | COMPLETED | 2024-05-20 | Cancer Center Sun Yat-sen Univ... More >>ersity, Guangzhou, Guangdong, 510060, China Less << | |
NCT01136967 | Unresectable Stage III|Stage I... More >>V Melanoma Less << | PHASE2 | COMPLETED | 2025-11-14 | Birmingham, Alabama, United St... More >>ates|Tucson, Arizona, United States|Los Angeles, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Boulder, Colorado, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Lakewood, Colorado, United States|Littleton, Colorado, United States|Lone Tree, Colorado, United States|Longmont, Colorado, United States|Parker, Colorado, United States|Thornton, Colorado, United States|Bonita Springs, Florida, United States|Bradenton, Florida, United States|Cape Coral, Florida, United States|Clearwater, Florida, United States|Englewood, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Naples, Florida, United States|North Port, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Port Charlotte, Florida, United States|Sarasota, Florida, United States|Sebring, Florida, United States|Tampa, Florida, United States|Venice, Florida, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Burnsville, Minnesota, United States|Coon Rapids, Minnesota, United States|Edina, Minnesota, United States|Fridley, Minnesota, United States|Maplewood, Minnesota, United States|Minneapolis, Minnesota, United States|Saint Paul, Minnesota, United States|Woodbury, Minnesota, United States|Southaven, Mississippi, United States|Saint Louis, Missouri, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|Morristown, New Jersey, United States|New York, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Springfield, Oregon, United States|Tualatin, Oregon, United States|Bethlehem, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Bartlett, Tennessee, United States|Franklin, Tennessee, United States|Gallatin, Tennessee, United States|Germantown, Tennessee, United States|Hermitage, Tennessee, United States|Lebanon, Tennessee, United States|Memphis, Tennessee, United States|Murfreesboro, Tennessee, United States|Nashville, Tennessee, United States|Smyrna, Tennessee, United States|Bedford, Texas, United States|Dallas, Texas, United States|Grapevine, Texas, United States|Houston, Texas, United States|Arlington, Virginia, United States|Fairfax, Virginia, United States|Gainesville, Virginia, United States|Leesburg, Virginia, United States|Winchester, Virginia, United States|Woodbridge, Virginia, United States|Vancouver, Washington, United States|Madison, Wisconsin, United States|Adelaide, Australia|Malvern, Australia|Newcastle, Australia|North Sydney, Australia|Perth, Australia|Westmead, Australia|Essen, Germany|Hannover, Germany|Heidelberg, Germany|Kiel, Germany|Mainz, Germany|Tubingen, Germany|Glasgow, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Surrey, United Kingdom Less << |
NCT02780310 | Adenoid Cystic Carcinoma | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-05-25 | Memorial Sloan Kettering Cance... More >>r Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States Less << |
NCT02792829 | Healthy Volunteers | PHASE1 | COMPLETED | 2025-08-14 | Las Vegas, Nevada, United Stat... More >>es Less << |
NCT00280397 | Cancer: Solid Tumors | PHASE1 | COMPLETED | 2025-11-08 | Tokyo, 104-0045, Japan |
NCT06417606 | Intrahepatic Cholangiocarcinom... More >>a Less << | PHASE4 | NOT_YET_RECRUITING | 2025-05-30 | Tongji Hospital, Wuhan, China |
NCT04447755 | Relapsed or Refractory Solid T... More >>umors Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-02-14 | Children's Hospital of Colorad... More >>o ( Site 0110), Aurora, Colorado, 80045, United States|Cleveland Clinic ( Site 0119), Cleveland, Ohio, 44195, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt ( Site 0102), Nashville, Tennessee, 37232, United States|Mary Crowley Cancer Research Center ( Site 0107), Dallas, Texas, 75230, United States|Hospital Universitario Austral ( Site 0126), Pilar, Buenos Aires, B1629ODT, Argentina|Hospital de Ni?os Ricardo Gutiérrez ( Site 0125), Ciudad Autonoma de Buenos Aires, Caba, C1425EFD, Argentina|Sydney Children's Hospital ( Site 0801), Randwick, New South Wales, 2031, Australia|Queensland Children s Hospital ( Site 0804), Brisbane, Queensland, 4101, Australia|Royal Childrens Hospital Melbourne ( Site 0802), Parkville, Victoria, 3052, Australia|Perth Children s Hospital ( Site 0803), Nedlands, Western Australia, 6009, Australia|UZ Gent ( Site 0250), Gent, Oost-Vlaanderen, 9000, Belgium|Klinicki bolnicki centar Rijeka ( Site 0726), Rijeka, Primorsko-goranska Zupanija, 51000, Croatia|Klinika za djecje bolesti Zagreb ( Site 0725), Zagreb, Zagrebacka Zupanija, 10000, Croatia|Fakultni Nemocnice Brno Bohunice ( Site 0651), Brno, Brno-mesto, 613 00, Czechia|Fakultni nemocnice v Motole ( Site 0650), Praha 5, 150 06, Czechia|Centre Leon-Berard ( Site 0326), Lyon, Auvergne, 69008, France|Hopital La Timone ( Site 0328), Marseille, Bouches-du-Rhone, 13005, France|Gustave Roussy ( Site 0327), Villejuif, Val-de-Marne, 94800, France|Institut Curie ( Site 0325), Paris, 75005, France|Unidad Nacional de Oncologia Pediatrica ( Site 0176), Guatemala, 01011, Guatemala|Medi-K Cayala ( Site 0177), Guatemala, 01016, Guatemala|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0678), Miskolc, Borsod-Abauj-Zemplen, 3526, Hungary|Semmelweis University ( Site 0675), Budapest, 1094, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 0677), Debrecen, 4032, Hungary|Chaim Sheba Medical Center ( Site 0500), Ramat-Gan, 5265601, Israel|IRCCS Ospedale Pediatrico Bambino Gesu ( Site 0410), Rome, Roma, 00165, Italy|A.O.Universitaria Meyer-Oncology & Haematology Unit ( Site 0400), Firenze, Toscana, 50139, Italy|Istituto Giannina Gaslini ( Site 0411), Genova, 16147, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0401), Milano, 20133, Italy|Ospedale Infantile Regina Margherita ( Site 0412), Torino, 10126, Italy|Asan Medical Center ( Site 0876), Songpagu, Seoul, 05505, Korea, Republic of|Seoul National University Hospital ( Site 0875), Seoul, 03080, Korea, Republic of|Starship Childrens Hospital ( Site 0826), Auckland, 1023, New Zealand|Clinica Anglo Americana ( Site 0203), San Isidro, Lima, 15073, Peru|Dmitry Rogachev National Research Center ( Site 0550), Moscow, Moskva, 117198, Russian Federation|St.Petersburg State Medical Univ. n.a. acad. I.P.Pavlov ( Site 0554), Saint Petersburg, Sankt-Peterburg, 197022, Russian Federation|Clinical Research Center of specialized types medical care-Oncology ( Site 0553), Saint-Petersburg, Sankt-Peterburg, 197758, Russian Federation|Institute for Oncology and Radiology of Serbia ( Site 0780), Belgrade, Beograd, 11000, Serbia|Univerzitetska decja klinika ( Site 0782), Beograd, 11000, Serbia|Wits Clinical Research ( Site 0579), Soweto, Gauteng, 2013, South Africa|Cancercare Rondebosch Oncology ( Site 0575), Cape Town, Western Cape, 7700, South Africa|Tygerberg Hospital ( Site 0578), Parow, Western Cape, 7505, South Africa|Hospital Universitario Sant Joan de Deu ( Site 0476), Esplugues de Llobregat, Barcelona, 08950, Spain|Hospital Nino Jesus ( Site 0477), Madrid, 28009, Spain|Skanes Universitetssjukhus Lund. ( Site 0525), Lund, Skane Lan, 221 85, Sweden|Hacettepe Universitesi Tip Fakultesi ( Site 0603), Ankara, 06100, Turkey|Istanbul Universitesi Onkoloji Enstitusu ( Site 0600), Istanbul, 34093, Turkey|Ege Universitesi Tip Fakultesi ( Site 0601), Izmir, 35040, Turkey|Dokuz Eylul Universitesi Arastirma Uygulama Hastanesi ( Site 0602), Izmir, 35330, Turkey Less << |
NCT03573960 | Thyroid Neoplasms | PHASE4 | ACTIVE_NOT_RECRUITING | 2024-12-30 | All India Institute of Medical... More >> Sciences, New Delhi, Delhi, 110029, India|Indraprastha Apollo Hospital, New Delhi, Delhi, 110076, India|Shetty's Hospital, Bangalore, Karnataka, 560068, India|Regional Cancer Centre, RCC, Thiruvananthapuram, Thiruvananthapuram, Kerala, 695011, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, 411004, India|All India Institute of Medical Sciences, Bhubaneshwar, Odisa, 751019, India|S. P. Medical College & A. G. Hospitals, Bīkaner, Rajasthan, 334003, India|Tata Memorial Hospital, Mumbai, 400012, India|BL Kapoor Hospital, New Delhi, New Delhi, 110005, India|Indrayani Hospital, Alandi, Pune, 412105, India|City Cancer Centre, Vijayawada, 520002, India Less << |
NCT00946153 | Hepatocellular Carcinoma | PHASE1|PHASE2 | COMPLETED | 2015-08-13 | Kashiwa-shi, Chiba, Japan|Kuru... More >>me-shi, Fukuoka, Japan|Sapporo-shi, Hokkaido, Japan|Kawasaki-shi, Kanagawa, Japan|Osaka-shi, Osaka, Japan|Osakasayama-shi, Osaka, Japan|Saga-shi, Saga, Japan|Chuo-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Musashino-shi, Tokyo, Japan|Gangnam-gu, Seoul, Korea, Republic of|Songpa-gu, Seoul, Korea, Republic of Less << |
NCT02199392 | P-glycoprotein|Healthy Volunte... More >>ers Less << | PHASE1 | COMPLETED | 2025-01-12 | Tacoma, Washington, 98418, Uni... More >>ted States Less << |
NCT03433703 | Carcinoma, Hepatocellular | PHASE2 | TERMINATED | 2019-01-07 | California Liver Research Inst... More >>itute, Pasadena, California, 91105, United States|University of Florida, Gainesville, Florida, 32611, United States|University of Louisville, Louisville, Kentucky, 40202, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States Less << |
NCT06138769 | Hepatocellular Carcinoma | PHASE2 | ACTIVE_NOT_RECRUITING | 2027-11-01 | Asan Medical Center, Seoul, 05... More >>505, Korea, Republic of Less << |
NCT05391867 | Hepatocellular Carcinoma | UNKNOWN | 2023-06-30 | Department of Hepatology, Dhak... More >>a, 1100, Bangladesh|Sir Salimullah Medical College, Dhaka, 1100, Bangladesh Less << | |
NCT04008082 | Carcinoma, Hepatocellular|Carc... More >>inoma|Neoplasms, Glandular and Epithelial|Neoplasms Less << | COMPLETED | 2022-01-28 | Eisai Trial Site #1, Osaka, Ja... More >>pan|Eisai Trial Site #2, Tokyo, Japan Less << | |
NCT02211222 | Differentiated Thyroid Cancer | APPROVED_FOR_MARKETING | 2025-06-15 | La Jolla, California, United S... More >>tates|Stanford, California, United States|Torrance, California, United States|Washington, District of Columbia, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Lansing, Michigan, United States|Lebanon, New Hampshire, United States|Neptune, New Jersey, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States Less << | |
NCT02726503 | Anaplastic Thyroid Cancer | PHASE2 | COMPLETED | 2020-03-20 | Nagoya University Hospital, Na... More >>goya-city, Aichi-prefecture, 466-8560, Japan|Fujita Health University Hospital, Toyoake-city, Aichi-prefecture, 470-1192, Japan|IUHW Ichikawa Hospital, Ichikawa-city, Chiba-prefecture, 272-0827, Japan|National Cancer Center Hospital East, Kashiwa-city, Chiba-prefecture, 277-8577, Japan|Japanese Red Cross Narita Hospital, Narita-city, Chiba-prefecture, 286-8523, Japan|Kuma Hospital, Kobe-city, Hyogo-prefecture, 650-0011, Japan|Kobe Univbersity Hospital, Kobe-city, Hyogo-prefecture, 650-0017, Japan|University of Tsukuba Hospital, Tsukuba-city, Ibaraki-prefecture, 305-8576, Japan|Iwate Medical University Hospital, Morioka-city, Iwate-prefecture, 020-8505, Japan|Kitasato University Hospital, Sagamihara-city, Kanagawa-prefecture, 252-0375, Japan|Showa University Northern Yokohama Hospital, Yokohama-city, Kanagawa-prefecture, 224-8503, Japan|Kanagawa Cancer Center, Yokohama-city, Kanagawa-prefecture, 241-8515, Japan|Miyaghi Cancer Center, Natori-city, Miyagi-prefecture, 981-1293, Japan|Tohoku University Hospital, Sendai-city, Miyagi-prefecture, 980-8574, Japan|Shinsyu University School of Medicine Department of Surgery, Matsumoto-city, Nagano-prefecture, 390-8621, Japan|Nara Hospital Kinki University Faculty of Medicine, Ikoma-city, Nara-prefecture, 630-0293, Japan|Nara Medical University, Kashihara-city, Nara-prefecture, 634-8522, Japan|Osaka Police Hospital, Osaka-city, Osaka-prefecture, 543-0035, Japan|Osaka City University Graduate School of Medicine and Faculty of Medicine, Osaka-city, Osaka-prefecture, 545-8585, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo-metropolis, 113-8603, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo-metropolis, 135-8550, Japan|Ito Hospital, Shibuya-ku, Tokyo-metropolis, 150-8308, Japan|Tokyo Medical University Hospital, Shinjuku-ku, Tokyo-metropolis, 160-0023, Japan Less << |
NCT00121719 | Solid Tumor or Lymphoma | PHASE1 | COMPLETED | 2019-03-01 | Netherlands Cancer Institute- ... More >>Antoni Van Leeuwenhoek Hospital, Amsterdam, 1066 Cx, Netherlands|Gartnavel General Hospital, Glasgow, G12 0Yn, United Kingdom Less << |
NCT02860936 | Adenoid Cystic Carcinomas of t... More >>he Salivary Glands Less << | PHASE2 | COMPLETED | 2025-06-19 | Fondazione IRCCS Istituto Nazi... More >>onale dei Tumori, Milan, 20133, Italy Less << |
NCT01111461 | Endometrial Cancer | PHASE2 | COMPLETED | 2025-10-15 | Phoenix, Arizona, United State... More >>s|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Honolulu, Hawaii, United States|Arlington Heights, Illinois, United States|Niles, Illinois, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Burnsville, Minnesota, United States|Edina, Minnesota, United States|Maplewood, Minnesota, United States|Minneapolis, Minnesota, United States|Saint Paul, Minnesota, United States|Woodbury, Minnesota, United States|Saint Louis, Missouri, United States|Morristown, New Jersey, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Cleveland, North Carolina, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Springfield, Oregon, United States|Tualatin, Oregon, United States|Charleston, South Carolina, United States|Austin, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Tyler, Texas, United States|Newport News, Virginia, United States|Norfolk, Virginia, United States|Virginia Beach, Virginia, United States|Vancouver, Washington, United States|Arlon, Belgium|Charleroi, Belgium|Duffel, Belgium|Ghent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Namur, Belgium|Oostende, Belgium|Roeselare, Belgium|Yvoir, Belgium|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Budapest, Hungary|Gyor, Hungary|Lublin, Poland|Poznan, Poland|Warsaw, Poland|Brasov County, Romania|Bucharest, Romania|Cluj County, Romania|Dolj County, Romania|Kazan, Russian Federation|Nizhny Novgorod, Russian Federation|Orenburg, Russian Federation|Petersburg, Russian Federation|Pyatigorsk, Russian Federation|Sochi,, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Syktyvkar, Russian Federation|Tomsk, Russian Federation|Tula, Russian Federation|Ufa, Russian Federation|Vladivostok, Russian Federation|Chernihiv, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Zaporizhia, Ukraine Less << |
NCT04415567 | Hepatocellular Carcinoma | COMPLETED | 2020-03-31 | Xinhua Hospital Affiliated to ... More >>Shanghai Jiao Tong University Medical School, Shanghai, 200092, China Less << | |
NCT02678780 | Neuroendocrine Tumors | PHASE2 | COMPLETED | 2025-08-20 | Universit?tsklinik für Innere ... More >>Medizin, Graz, 8036, Austria|Medizinische Universit?t Wien, Wien, a-1090, Austria|Spedali Civili di Brescia, Brescia, Italy|Instituto Oncologico Mediterraneo, Catania, Italy|Azienda Ospedaliero Universitaria Careggi - SC di Oncologia, Firenze, 50139, Italy|IRST of Meldola, Meldola, Italy|Istituto Europeo di Oncologia - Unità di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini, Milano, 20141, Italy|AOU Policlinico di Modena - DH Oncologico, Modena, 41124, Italy|IRCCS Napoli, Napoli, Italy|Hospital Universatorio de Verona, Verona, Italy|Hospital Virgen de la Victoria, Málaga, Andalucía, 29010, Spain|Hospital Central de Asturias, Oviedo, Asturias, 33006, Spain|Hospital Marqués de Valdecilla, Santander, Cantabria, 39011, Spain|Hospital de Donostia, Donostia, País Vasco, Spain|Hospital Universitario Vall Hebrón, Barcelona, 08035, Spain|ICO Hospitalet, L′Hospitalet de Llobregat, 08908, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario la Paz, Madrid, 28046, Spain|Hospital Miguel Servet, Zaragoza, 50009, Spain|Beatson Oncology Centre Gartnavel General Hospital, Glasgow, G12 0YN, United Kingdom|Christie Hospital, Manchester, Manchester, M20 4BX, United Kingdom Less << |
NCT04053972 | Hepatocellular Carcinoma | PHASE3 | UNKNOWN | 2022-12-31 | SUN YAT-SEN University Cancer ... More >>Center, Guangzhou, Guangdong, 510060, China Less << |
NCT04656249 | Cholangiocarcinoma|Biliary Tra... More >>ct Cancer|Targeted Therapy Less << | PHASE2 | COMPLETED | 2021-05-01 | Chinese Academy of Medical Sci... More >>ences & Peking Union Medical College Hospital, Beijing, Beijing, 100730, China Less << |
NCT02199379 | Renal Impairment|Disease Sever... More >>ity Less << | PHASE1 | COMPLETED | 2025-10-12 | Orlando, Florida, 32809, Unite... More >>d States|Minneapolis, Minnesota, 55404, United States|Knoxville, Tennessee, 37920, United States Less << |
NCT02430714 | Thyroid Neoplasms | COMPLETED | 2016-11-06 | Osaka, Japan|Tokyo, Japan | |
NCT03663114 | Carcinoma, Hepatocellular | COMPLETED | 2020-02-20 | Eisai trial site 1, Osaka, Jap... More >>an|Eisai trial site 2, Tokyo, Japan Less << | |
NCT00121680 | Metastatic Melanoma | PHASE1 | COMPLETED | 2025-05-15 | Dallas, Texas, United States|H... More >>ouston, Texas, United States Less << |
NCT04297254 | Carcinoma, Hepatocellular | PHASE4 | COMPLETED | 2023-07-31 | HCG Comprehensive Cancer Care ... More >>Hospital, Bangalore, Karnataka, 560027, India|Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, 422002, India|Shatabdi Hospital, Nashik, Maharashtra, 422005, India|Apex Wellness Hospital, Nashik, Maharashtra, 422009, India|LMMF's Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, 411004, India|Noble Hospital, Pune, Maharashtra, 411013, India|Somani Hospital, Jaipur, Rajasthan, 302019, India|Meenakshi Mission Hospital, Madurai, Tamil Nadu, 625107, India|Apollo Gleneagles Hospital Limited, Kolkata, West Bengal, 700054, India Less << |
NCT01268293 | Cancer | PHASE1 | COMPLETED | 2025-04-13 | Chuo-ku, Tokyo, Japan |
NCT02579616 | Biliary Tract Cancer | PHASE2 | COMPLETED | 2019-02-27 | Nagoya, Aichi, Japan|Kashiwa, ... More >>Chiba, Japan|Yokohama, Kanagawa, Japan|Ina-machi, Saitama, Japan|Chuo-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Mitaka, Tokyo, Japan Less << |
NCT05221775 | First-line Treatment|Advanced ... More >>Gastric Carcinoma Less << | PHASE1 | UNKNOWN | 2023-10-01 | Tianjin Medical University Can... More >>cer Institute and Hospital, Tianjin, China Less << |
NCT02846766 | Cancer | PHASE2 | WITHDRAWN | 2021-06-01 | University of California, San ... More >>Diego, La Jolla, California, 92093, United States|Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, 60611, United States Less << |
NCT04428437 | Hepatocellular Carcinoma | TERMINATED | 2023-09-30 | Humanity & Health Clinical Tri... More >>al Centre, Hong Kong, Hong Kong SAR, Hong Kong Less << | |
NCT02578316 | Advanced Solid Tumors|Lymphoma... More >>s Less << | PHASE1 | COMPLETED | 2025-10-10 | Amsterdam, Netherlands |
NCT05789667 | Differentiated Thyroid Cancer|... More >>Gender Less << | RECRUITING | 2025-12-31 | Regina Elena National Cancer I... More >>nstitute, Rome, 00144, Italy Less << | |
NCT01877083 | KIF5B-RET-Positive Adenocarcin... More >>oma of the Lung Less << | PHASE2 | COMPLETED | 2017-11-02 | Duarte, California, United Sta... More >>tes|La Jolla, California, United States|Whittier, California, United States|Jacksonville, Florida, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Hong Kong, Hong Kong|Sha Tin, Hong Kong|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Akashi, Hyogo, Japan|Kobe, Hyogo, Japan|Natori, Miyagi, Japan|Osaka-Sayama, Osaka, Japan|Chuo-ku, Tokyo, Japan|Koto-Ku, Tokyo, Japan|Fukuoka, Japan|National Cancer Center Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|National Taiwan University Hospital, Taipei, Taiwan|Veterans General Hospital Taipei, Taipei, Taiwan Less << |
NCT03533361 | Thyroid Cancer | APPROVED_FOR_MARKETING | - | Hospital Sirio Libanes, Sao Pa... More >>ulo, S?o Paulo, 01246-000, Brazil Less << | |
NCT05901194 | Hepatocellular Carcinoma Non-r... More >>esectable Less << | PHASE1|PHASE2 | NOT_YET_RECRUITING | 2025-07-27 | Hospital Haut levêque, Bordeau... More >>x, France|Hospital Henri Mondor, Créteil, France|Hospital Claude Huriez, Lille, France|Pontchaillou Hospital, Rennes, France|Hospital Trousseau, Tours, France|Paul Brousse Hospital, Villejuif, France Less << |
NCT03801499 | Intrahepatic Cholangiocarcinom... More >>a Less << | PHASE2 | WITHDRAWN | 2025-12-19 | Cancer Center Sun Yat-sen Univ... More >>ersity, Guangzhou, Guangdong, 510060, China Less << |
NCT02953743 | Unresectable Hepatocellular Ca... More >>rcinoma (HCC) Less << | PHASE1 | COMPLETED | 2020-12-28 | Harbin Medical University Canc... More >>er Hospital, Harbin, Heilongjiang, China|Shanghai Cancer Hospital, Fudan University, Shanghai, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China Less << |
NCT02421042 | Hepatic Impairment|Hepatic Fun... More >>ction Less << | PHASE1 | COMPLETED | 2025-07-12 | Miami, Florida, 33014, United ... More >>States|Miami, Florida, 33169, United States|Orlando, Florida, 32809, United States|Minneapolis, Minnesota, 55404, United States|Knoxville, Tennessee, 37920, United States Less << |
NCT03506048 | Differentiated Thyroid Gland C... More >>arcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma Less << | PHASE2 | TERMINATED | 2021-06-24 | Emory University Hospital/Wins... More >>hip Cancer Institute, Atlanta, Georgia, 30322, United States Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.34mL 0.47mL 0.23mL |
11.71mL 2.34mL 1.17mL |
23.43mL 4.69mL 2.34mL |